<code id='9C9BC46218'></code><style id='9C9BC46218'></style>
    • <acronym id='9C9BC46218'></acronym>
      <center id='9C9BC46218'><center id='9C9BC46218'><tfoot id='9C9BC46218'></tfoot></center><abbr id='9C9BC46218'><dir id='9C9BC46218'><tfoot id='9C9BC46218'></tfoot><noframes id='9C9BC46218'>

    • <optgroup id='9C9BC46218'><strike id='9C9BC46218'><sup id='9C9BC46218'></sup></strike><code id='9C9BC46218'></code></optgroup>
        1. <b id='9C9BC46218'><label id='9C9BC46218'><select id='9C9BC46218'><dt id='9C9BC46218'><span id='9C9BC46218'></span></dt></select></label></b><u id='9C9BC46218'></u>
          <i id='9C9BC46218'><strike id='9C9BC46218'><tt id='9C9BC46218'><pre id='9C9BC46218'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:95
          Illumina building. -- biotech coverage from STAT
          Adobe

          LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

          The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

          advertisement

          The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules. 

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more
          Roche’s Alnylam deal shows drug firms interested in heart drugs
          Roche’s Alnylam deal shows drug firms interested in heart drugs

          AdobeRoche’sannouncementMondaythatitwouldpay$310millionforrightstoahypertensiontreatment,zilebesiran

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          EU regulator recommends expanding Mounjaro approval to obesity

          PauloAmorim/VWPicsviaAPImagesLONDON—TwodaysaftersimilardecisionsintheU.S.andU.K.,regulatorsinEuropeo